Jaguar health and napo pharmaceuticals provide key findings from cancer-related diarrhea abstracts submitted to asco for june 2021 annual meeting

San francisco, ca / accesswire / may 20, 2021 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("crd") by napo pharmaceuticals, inc. ("napo"), jaguar's wholly owned subsidiary, and napo's collaborators that has been accepted for poster presentation at the american society of clinical oncology (asco®) annual meeting, which will be held virtually from june 4-8, 2021. in addition, two crd-related abstracts from napo and its collaborators have been accepted for online publication at asco.
JAGX Ratings Summary
JAGX Quant Ranking